- Home
- AUTL vs PLRX Comparison
AUTL vs PLRX Comparison
Compare AUTL & PLRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | AUTL | PLRX |
|---|---|---|
| Founded | 2014 | 2015 |
| Country | United Kingdom | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 431.2M | 81.1M |
| IPO Year | 2025 | 2020 |
Fundamental Metrics
Financial Performance| Metric | AUTL | PLRX |
|---|---|---|
| Price | $1.49 | $1.35 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 4 | 4 |
| Target Price | ★ $8.50 | $2.67 |
| AVG Volume (30 Days) | ★ 1.6M | 558.0K |
| Earning Date | 05-07-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 29.97 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $10,120,000.00 | N/A |
| Revenue This Year | $85.73 | N/A |
| Revenue Next Year | $70.87 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 496.00 | N/A |
| 52 Week Low | $1.11 | $1.09 |
| 52 Week High | $2.70 | $1.95 |
Technical Indicators
Market Signals| Indicator | AUTL | PLRX |
|---|---|---|
| Relative Strength Index (RSI) | 54.58 | 56.43 |
| Support Level | $1.45 | $1.12 |
| Resistance Level | $1.52 | $1.36 |
| Average True Range (ATR) | 0.08 | 0.07 |
| MACD | 0.01 | 0.01 |
| Stochastic Oscillator | 98.46 | 87.50 |
Price Performance
Historical ComparisonAbout AUTL Autolus Therapeutics plc
Autolus Therapeutics PLC is a biopharmaceutical company developing next-generation programmed T-cell therapies for the treatment of cancer. The company's clinical-stage pipeline comprises Obe-cel (obecabtagene autoleucel), AUTO1/22, AUTO3, AUTO5, AUTO6, AUTO7 & AUTO8.
About PLRX Pliant Therapeutics Inc.
Pliant Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the discovery and development of integrin-based therapies. The company operates as a single reportable segment focused on developing and commercializing novel integrin-based treatments. Its lead product candidate, PLN-101095, is an oral small molecule targeting integrins for the treatment of solid tumors. The company also advances a pipeline of integrin-based programs across multiple disease areas through its proprietary drug discovery platform.